News Releases

Company to host conference call on Monday, August 16 at 8:00 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 13, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it

John Knighton to join Sesen Bio as Vice President and Chief Compliance Officer The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 11, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company

The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 The Company also believes it remains on track for potential approval in Europe and key markets in MENA in 2022 Strengthened balance sheet with $151M in cash and cash equivalents as of June 30,

Sesen Bio to receive $1.5 million upfront and is eligible for additional regulatory and commercial milestone payments Sesen Bio is entitled to receive a 30% royalty on net sales in Turkey CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company

Company announces hiring of Amy Ponpipom as Vice President, Assistant General Counsel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today

Hiring of the US sales force is 97% complete and sales training has commenced 14 Key Opinion Leader (KOL) speakers have been identified and speaker training has commenced Two-pronged market access and reimbursement strategy has commenced CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.

Peter K Honig, MD, MPH and Michael A.S. Jewett , MD, FRCSC, FACS have joined the Sesen Bio Board of Directors as the Company nears potential US approval of Vicineum™ in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company

Anticipated submission of product market application for Vicineum in China in 2022, with potential approval in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of

No Advisory Committee meeting is planned at this time No confirmatory trial required at this time Company believes it remains on track for August 18 th target PDUFA date CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 14, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to four new employees in connection with